Literature DB >> 25730189

A time to stop, a time to start: high-dose chemotherapy in overweight and obese patients.

N A Berger1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25730189     DOI： 10.1038/bmt.2015.26

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  19 in total

1.  Effects of a partly self-administered exercise program before, during, and after allogeneic stem cell transplantation.

Authors:  Joachim Wiskemann; Peter Dreger; Rainer Schwerdtfeger; Andrea Bondong; Gerhard Huber; Nikolaus Kleindienst; Cornelia M Ulrich; Martin Bohus
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

2.  Outcomes after autologous SCT in lymphoma patients grouped by weight.

Authors:  J E Lau; C Weber; M Earl; L A Rybicki; K D Carlstrom; C M Wenzell; B T Hill; N S Majhail; M Kalaycio
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

Review 3.  Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.

Authors:  Jennifer J Griggs; Pamela B Mangu; Holly Anderson; Edward P Balaban; James J Dignam; William M Hryniuk; Vicki A Morrison; T May Pini; Carolyn D Runowicz; Gary L Rosner; Michelle Shayne; Alex Sparreboom; Lara E Sucheston; Gary H Lyman
Journal:  J Clin Oncol       Date:  2012-04-02       Impact factor: 44.544

Review 4.  Chemotherapy dosing in overweight and obese patients with cancer.

Authors:  Gary H Lyman; Alex Sparreboom
Journal:  Nat Rev Clin Oncol       Date:  2013-07-16       Impact factor: 66.675

5.  Evaluation of chemotherapy-induced severe myelosuppression incidence in obese patients with capped dosing.

Authors:  Monique D Lopes-Serrao; Sarah M Gressett Ussery; Ronald G Hall; Sachin R Shah
Journal:  J Oncol Pract       Date:  2011-01       Impact factor: 3.840

6.  Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft.

Authors:  C Tarella; D Caracciolo; P Gavarotti; C Argentino; F Zallio; P Corradini; D Novero; C Magnani; A Pileri
Journal:  Bone Marrow Transplant       Date:  2000-12       Impact factor: 5.483

7.  Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults.

Authors:  Willis H Navarro; Manza-A Agovi; Brent R Logan; Karen Ballen; Brian J Bolwell; Haydar Frangoul; Vikas Gupta; Theresa Hahn; Vincent T Ho; Mark Juckett; Hillard M Lazarus; Mark R Litzow; Jane L Liesveld; Jan S Moreb; David I Marks; Philip L McCarthy; Marcelo C Pasquini; J Douglas Rizzo
Journal:  Biol Blood Marrow Transplant       Date:  2010-04-20       Impact factor: 5.742

8.  Impact of patient weight on non-relapse mortality after marrow transplantation.

Authors:  H J Deeg; K Seidel; B Bruemmer; M S Pepe; F R Appelbaum
Journal:  Bone Marrow Transplant       Date:  1995-03       Impact factor: 5.483

Review 9.  Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee.

Authors:  Joseph Bubalo; Paul A Carpenter; Navneet Majhail; Miguel-Angel Perales; David I Marks; Paul Shaughnessy; Joseph Pidala; Helen L Leather; John Wingard; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-23       Impact factor: 5.742

10.  Race, age, and obesity disparities in adult physical activity levels in breast cancer patients and controls.

Authors:  Cheryl L Thompson; Cynthia Owusu; Nora L Nock; Li Li; Nathan A Berger
Journal:  Front Public Health       Date:  2014-09-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.